This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

MAKE THE MenB CONVERSATION A PART OF YOUR PROTOCOL

As part of the CDC recommendation on MenB vaccination, it’s important to have a discussion with patients and their parents.

CDC recently revised the language pertaining to MenB vaccination in the CDC Immunization Schedules.

A primary series for meningitis B vaccination is recommended for adolescents not at increased risk age 16–23 years (preferred age 16–18 years) based on shared clinical decision-making.1

It’s possible patients and their parents are unaware of MenB—that’s why it’s crucial you initiate the MenB conversation and involve them in the vaccination decision.

Make sure you cover the following topics as part of your MenB conversation:

EDUCATE

on what meningococcal disease is and the 5 vaccine-preventable serogroups, including serogroup B2,3

INTRODUCE

patients to BEXSERO and explain that it can help protect against MenB4

REMIND

patients that BEXSERO is typically covered for 99% of commercially insured patients5,*

START

the BEXSERO 2-dose vaccination series for your appropriate patients4

SCHEDULE

the 2nd dose and provide follow-up reminders to help patients complete the series

  •   *When provided by an in-network provider. Coverage, coding, cost to patient, reimbursement amount for product, and administration fee will vary by payer, plan, professional setting, or services rendered and are subject to change without notice. Cost to patients may vary. Coverage and reimbursement decisions are made by individual payers following receipt of claims from providers. Providers must follow documentation and billing requirements of payer.

CDC=Centers for Disease Control and Prevention.

Indication


BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.


Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

References

  1. Centers for Disease Control and Prevention. Immunization schedules: Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html. Updated February 3, 2020. Accessed February 6, 2020.
  2. Centers for Disease Control and Prevention. Meningococcal vaccination for adolescents: Information for healthcare professionals. https://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Updated July 26, 2019. Accessed February 3, 2020.
  3. Centers for Disease Control and Prevention. Meningococcal disease: Causes and transmission. https://www.cdc.gov/meningococcal/about/causes-transmission.html. Updated May 31, 2019. Accessed February 3, 2020.
  4. Prescribing Information for BEXSERO.
  5. Managed Markets Insight & Technology, LLC, Database as of December 2019.

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

Important Safety Information for BEXSERO

  • BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
  • Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
  • Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
  • Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
  • Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
  • Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.